How are energy investors positioned?
TORONTO - InnoMed Tech Ltd., a medical device company, has received conditional approval from the TSX Venture Exchange (TSXV) to list its common shares, a move that marks a significant step for the company’s growth strategy. The approval, contingent upon the company meeting specific TSXV requirements within 90 days from May 20, 2025, was announced today.
The company, known for its focus on medical devices and sciences, is advancing its PureFlowCath Catheter System for Continuous Irrigation (CSCI), designed to mitigate urinary tract infections associated with urinary catheters. InnoMed Tech has been granted various patents, including the European Patent, and aims to bring its CSCI system to market.
InnoMed Tech’s CEO, Rob Rhodes, expressed satisfaction with the conditional listing, viewing it as a reflection of the company’s dedication to shareholder value and its commitment to introducing medical innovations that enhance clinical outcomes.
Investors are encouraged to review the company’s final Non-offering Long Form Prospectus, which has been filed with the British Columbia Securities Commission and contains detailed information about the company’s business and associated investment risks. The Prospectus is accessible on the SEDAR+ website and the company’s official site.
This development comes with a cautionary note that the TSXV has not endorsed the adequacy or accuracy of the press release, and the statements within may contain forward-looking information subject to various risks and uncertainties. The actual results could significantly differ from those projected.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.